Open AccessImmunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications
Author(s) -
Erin Armideo,
Colleen Callahan,
Lara Madonia
Publication year - 2017
Publication title -
journal of the advanced practitioner in oncology
Language(s) - English
Resource type - Journals
eISSN - 2150-0886
pISSN - 2150-0878
DOI - 10.6004/jadpro.2017.8.1.4
Subject(s) - medicine , intensive care medicine , multidisciplinary approach , immunotherapy , front line , disease , clinical trial , multidisciplinary team , clinical practice , health care , population , cancer , nursing , social science , environmental health , sociology , political science , law , economics , economic growth
Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials. Immunotherapy has become the standard of care for patients with high-risk disease, and many institutions across the country are providing this therapy. The care of these patients is complex and often associated with many side effects. The purpose of this article is to review the most common side effects seen in clinical practice and examine their management. Furthermore, this article will discuss the need for a consistent and educated multidisciplinary front-line team to care for these patients, with advanced practitioners playing a lead role to provide the care and attention needed for this patient population.